


Please amend claims 8 and 15 and add new claims 19 to 25 as follows before calculating the filing fee for the above-identified application:

7 8. (Amended) Process for the preparation of a compound of formula (I) according to [any one of] Claim[s] 1 [to 5 and 7], characterized in that:

(1) either when  $Z = NR_{11}R_{12}$ , in which  $R_{11}$  and  $R_{12}$  are as defined for (1):

(1a) when at least one of the  $R_{11}$  and  $R_{12}$  radicals is different from hydrogen, a compound of formula:

7810X




in which  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $W$ ,  $Cy$  and  $T$  are as defined for (I) and in which  $X$  is a halogen or a sulphonic acid derivative is reacted with a derivative of formula  $ZH$  in a solvent selected from dimethylformamide, tetrahydrofuran or acetonitrile, at temperatures of between  $0^\circ$  and  $120^\circ C$ ;

(1b) when  $R_{11}$  and  $R_{12} = H$ , the compound (IIA), in which  $X$  is an azido, is reduced to amino;

(2) or, when  $Z = -COOH$ , a compound of formula:

7811X




in which  $R_1$ ,  $R_2$ ,  $W$ ,  $R_3$ ,  $R_4$  and  $Cy$  are as defined for (I) and  $T'$  represents  $T-CH_2-$ , is oxidized in an acid solvent at a temperature of between  $0^\circ C$  and  $100^\circ C$ , alkali metal dichromates or alkali metal or alkaline-earth metal permanganates;

(3) or a compound of formula:


81

7820X



in which  $R_1$ ,  $R_2$ , Cy, T and Z are as defined for (I), is reacted with a compound of formula:


7821X



in which W,  $R_3$  and  $R_4$  are as defined for (I) and Hal represents a halogen atom, in an anhydrous solvent in the presence of a metal hydride or an alkali metal alkoxide at temperatures of between  $-40^\circ$  and  $25^\circ\text{C}$ ;


(4) or, when  $Z = -\text{COOH}$ , a compound of formula:

7822X



in which  $R_1$ ,  $R_2$  and Cy are as defined above for (I) and  $T'$  represents  $T-\text{CH}_2$ , is oxidized [to (I)], then the acid thus obtained of formula:


7823X



in which  $R_1$ ,  $R_2$ , Cy and T are as defined above for (I), is subsequently optionally protected by a protective group for the carboxylic acid, in order to obtain the intermediate of formula:

82

T830X



in which R<sub>1</sub>, R<sub>2</sub>, Cy and T are as defined for (I) and P represents a protective group chosen from an alkyl, a *tert*-butyl or a benzyl, and, finally, this compound (II"BP) is subjected to the action of a derivative of formula (2) in order to obtain, after deprotection, a compound (I); one of its quaternary ammoniums, oxides, sulphones or salts.

*Acont*  
*14*  
15. (Amended) Pharmaceutical composition according to [any one of] Claim[s] 8 [to 14]  
also containing another active principle.  
*a2*

Please add the following new claims:

*18*  
--18. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.--

*19*  
--19. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.--

*20*  
--20. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.--

*21*  
--21. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.--

*22*  
--22. A method for the treatment of diseases in which the vasopressin and/or oxytocin receptor is involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.--

*23*